Advice
in the absence of a submission from the holder of the marketing authorisation
cannabinoid oromucosal spray (Sativex®) is not recommended for use within NHS Scotland.
Indication under review: as an add-on treatment for symptom improvement in patients with moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice68KB (PDF)
Medicine details
- Medicine name:
- cannabinoid (Sativex)
- SMC ID:
- 703/11
- Indication:
- as an add-on treatment for symptom improvement in patients with moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy.
- Pharmaceutical company
- Bayer plc/Bayer Schering Pharma
- BNF chapter
- Musculoskeletal and joint diseases
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published:
- 11 April 2011